For the latest updates on our ongoing response to COVID-19, please click here.

        Pipeline

        The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases.

        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

        Pipeline

        Viral?Diseases

        • Biktarvy

          HIV treatment pediatric1

          Phase 1
          Phase 2
          Phase 3
        • Capsid inhibitor (GS-6207)

          HIV HTE2

          Phase 1
          Phase 2
          Phase 3
        • Capsid inhibitor (GS-6207)

          HIV treatment na?ve

          Phase 1
          Phase 2
          Phase 3
        • Vesatolimod (GS-9620, TLR-7 agonist)

          HIV cure

          Phase 1
          Phase 2
          Phase 3
        • Elipovimab (GS-9722, bNab)

          HIV cure

          Phase 1
          Phase 2
          Phase 3
        • Selgantolimod (GS-9688, TLR-8 agonist)

          HBV cure

          Phase 1
          Phase 2
          Phase 3
        • PD-L1 inhibitor (GS-4224)

          HBV cure

          Phase 1
          Phase 2
          Phase 3

        1 Biktarvy HIV treatment pediatric label extension.

        2 Registrational for heavily treatment-experienced (HTE) patients.

        Inflammatory diseases

        • Filgotinib (GS-6034, JAK-1 inhibitor)

          Rheumatoid arthritis

          Phase 1
          Phase 2
          Phase 3
        • Filgotinib (GS-6034, JAK-1 inhibitor)

          Ulcerative colitis

          Phase 1
          Phase 2
          Phase 3
        • Filgotinib (GS-6034, JAK-1 inhibitor)

          Crohn's disease

          Phase 1
          Phase 2
          Phase 3
        • Filgotinib (GS-6034, JAK-1 inhibitor)

          Psoriatic arthritis

          Phase 1
          Phase 2
          Phase 3
        • Filgotinib (GS-6034, JAK-1 inhibitor)

          Ankylosing spondylitis

          Phase 1
          Phase 2
          Phase 3
        • Filgotinib (GS-6034, JAK-1 inhibitor)

          Uveitis

          Phase 1
          Phase 2
          Phase 3
        • TPL2 inhibitor (GS-4875)

          Ulcerative colitis

          Phase 1
          Phase 2
          Phase 3
        • GLPG-19721

          Osteoarthritis

          Phase 1
          Phase 2
          Phase 3
        • GLPG-05551

          Inflammatory diseases

          Phase 1
          Phase 2
          Phase 3
        • GLPG-33121

          Inflammatory diseases

          Phase 1
          Phase 2
          Phase 3
        • GLPG-39701

          Inflammatory diseases

          Phase 1
          Phase 2
          Phase 3
        • GLPG-36671

          Inflammatory diseases

          Phase 1
          Phase 2
          Phase 3

        1 Optionable partner program.

        Fibrotic Diseases

        • Cilofexor (GS-9674, FXR agonist)

          PSC

          Phase 1
          Phase 2
          Phase 3
        • GLPG-16901

          Idiopathic Pulmonary Fibrosis

          Phase 1
          Phase 2
          Phase 3
        • Cilofexor (FXR agonist)

          NASH

          Phase 1
          Phase 2
          Phase 3
        • Firsocostat (ACC inhibitor)

          NASH

          Phase 1
          Phase 2
          Phase 3
        • Selonsertib (ASK1 inhibitor) combinations

          NASH

          Phase 1
          Phase 2
          Phase 3
        • Selonsertib (GS-4997, ASK1 inhibitor)

          DKD

          Phase 1
          Phase 2
          Phase 3
        • GLPG-16901

          Systemic sclerosis

          Phase 1
          Phase 2
          Phase 3
        • GLPG-12052

          Idiopathic pulmonary fibrosis

          Phase 1
          Phase 2
          Phase 3

        1 Optioned parter program.

        2 Optionable partner program.

        Oncology

        • KTE-X19

          MCL

          Phase 1
          Phase 2
          Phase 3
        • Axi-cel

          2L DLBCL

          Phase 1
          Phase 2
          Phase 3
        • Axi-cel

          Indolent NHL

          Phase 1
          Phase 2
          Phase 3
        • Axi-cel

          1L DLBCL

          Phase 1
          Phase 2
          Phase 3
        • Axi-cel

          DLBCL (+rituximab or lenalidomide)

          Phase 1
          Phase 2
          Phase 3
        • KTE-X19

          Adult ALL

          Phase 1
          Phase 2
          Phase 3
        • KTE-X19

          Pediatric ALL

          Phase 1
          Phase 2
          Phase 3
        • KTE-X19

          CLL

          Phase 1
          Phase 2
          Phase 3
        • Axi-cel

          DLBCL (utomilumab)

          Phase 1
          Phase 2
          Phase 3
        • KITE-718 (MAGE A3/A6)

          Solid tumor

          Phase 1
          Phase 2
          Phase 3
        • KITE-439 (HPV E7)

          Solid tumor

          Phase 1
          Phase 2
          Phase 3
        • Oral PD-L1 inhibitor (GS-4224)

          Solid tumor

          Phase 1
          Phase 2
          Phase 3
        • anti-CD73/TGF? TRAP (GS-1423)1

          Solid tumor

          Phase 1
          Phase 2
          Phase 3
        • Bi-specific mAb (AGEN1223)2,3,4

          Multiple

          Phase 1
          Phase 2
          Phase 3
        • Anti-CD137 mAb mAb (AGEN2373)3,4

          Multiple

          Phase 1
          Phase 2
          Phase 3

        1 TME conditioning anti-CD73/TGF? TRAP bifunctional fusion protein (GS-1423).

        2 Bi-specific mAb targeting immunosuppressive regulatory T cells (AGEN1223).

        3 Exclusive option to license right from Agenus upon proof of concept data.

        4 Optionable partner program. ALL - Acute lymphocytic leukemia. CLL - Chronic lymphocytic leukemia. DLBCL - Diffuse large B-cell lymphoma. iNHL - Indolent non-Hodgkin lymphoma. MCL - Mantle cell lymphoma. r/r - relapsed refractory. iNHL - Indolent non-Hodgkin lymphoma.

        午夜tv特色视频